Pacific Biosciences of California Analysis (March 2026)

Pacific Biosciences ...

NasdaqGS:PACB

$ 1,35

$-0,05 (-3,57%)

1,35 $

$-0,05 (-3,57%)

End-of-day quote: 03/26/2026

Pacific Biosciences of California Stock Value

The analyst rating for NasdaqGS:PACB is currently Outperform.

Outperform

Pacific Biosciences of California Company Info

EPS Growth 5Y

3,09%

Market Cap

$0,41 B

Long-Term Debt

$0,65 B

Short Interest

4,78%

Quarterly earnings

05/08/2026 (E)

Dividend

$0,00

Dividend Yield

0,00%

Founded

2000

Industry

Health Care

Country

United States

ISIN Number

US69404D1081

Website

http://www.pacb.com

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

$3,00

122.22%

Last Update: 03/23/2026

Analysts: 7

Highest Price Target $3,00

Average Price Target $3,00

Lowest Price Target $1,50

In the last five quarters, Pacific Biosciences of California’s Price Target has fallen from $15,65 to $12,67 - a -19,04% decrease. Six analysts predict that Pacific Biosciences of California’s share price will increase in the coming year, reaching $3,00. This would represent an increase of 122,22%.

Top growth stocks in the health care sector (5Y.)

What does Pacific Biosciences of California do?

Pacific Biosciences of California, Inc. operates as a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. The company’s products and technology under development stem from two highly differentiated core technologies focused on accuracy, quality, and completeness, which include its HiFi long-r...

The company’s products and technology under development stem from two highly differentiated core technologies focused on accuracy, quality, and completeness, which include its HiFi long-read sequencing technology and its Sequencing by Binding (SBB) short-read sequencing technology. The company’s products address solutions across a broad set of applications, including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. Long-read sequencing has been applied to produce telomere-to-telomere genomes of humans, pangenome references, and has been recognized for its ability to provide more complete views of human variation.

The company’s focus is on creating some of the world's most advanced sequencing systems to provide its customers with the most complete and accurate view of genomes, transcriptomes, and epigenomes.

Recent Developments

In 2024, the company launched Vega, a revolutionary new benchtop sequencer designed to make accurate long-read sequencing accessible to more laboratories than ever before. Vega delivers up to 60 gigabases of long reads per run and is designed to provide accurate HiFi reads and high-quality genomic, transcriptomic, and epigenetic data for individual labs.

Additionally, in the fourth quarter of 2024, the company launched SPRQ chemistry for the Revio system. The SPRQ chemistry will increase the efficiency of loading on Revio SMRT Cells, reducing DNA input requirements to just 500 ng, a 75% reduction. These lower input requirements will allow HiFi sequencing to support new sample types, such as saliva and tumors.

In the first quarter of 2024, the company commenced commercial shipments for the PureTarget repeat expansion panel, a new solution designed to comprehensively analyze 20 genes associated with serious neurological disorders, including challenging-to-sequence genes with tandem repeat expansions. The company also released the Nanobind PanDNA kit as a single kit that supports the extraction of high-quality DNA from many sample types, and the HiFi prep kit as a scalable and automation-friendly library prep for genomic samples.

Principal Markets

Researchers utilize the company’s solutions in human genomics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications.

Technology, Products, and Solutions

The company has developed HiFi long-read sequencing based on Single-Molecule Real-Time (SMRT) technology, which accurately detects the nucleotide sequence and epigenetic status of individual DNA molecules. The company is also expanding its genomic solutions with its short-read SBB chemistry, which offers sensitive sequencing for short-read applications.

The company’s sales consist of sequencing instruments, nanofluidic chips (SMRT Cells), and reagents for preparing DNA and performing sequencing based on its SMRT technology; flow cells and reagents for preparing DNA and performing sequencing based on its SBB technology; reagents for DNA extraction based on its Nanobind technology; and the services it performs for customers.

HiFi Long-Read Sequencing

The company’s HiFi long-read sequencing protocol was built upon its SMRT sequencing systems, including consumables and software, and offers customized end-to-end workflows for different sequencing applications. Highly accurate, long sequence reads simplify and accelerate data analysis algorithms, reducing the need for error correction and/or assembly, depending on the application.

Customers use the company’s HiFi long-read sequencing platforms in a wide range of sequencing applications, including whole genome sequencing and de novo genome assembly, long-range phasing, targeted sequencing, full-length RNA and single-cell sequencing, characterization of metagenomic communities and other mixed DNA samples, viral genome sequencing, and others. The company’s technology is also capable of detecting epigenetic markers simultaneously by analyzing the kinetics of DNA polymerization that is affected, and thereby detectable, by epigenetic markers, such as 5-methylcytosine or N6-methyladenine.

SMRT Technology

The company’s proprietary SMRT Technology enables the observation of DNA synthesis as it occurs in real time by harnessing the natural process of DNA replication, which in nature is a highly efficient and accurate process actuated by DNA polymerases. DNA polymerases attach to a strand of DNA to be replicated, examine the individual base at the point it is attached, and then determine which of the four building blocks, or nucleotides (A, C, G, or T), is required to complement that individual base. After determining which nucleotide is required, the polymerases incorporate that nucleotide into the growing strand being produced.

SMRT Sequencing is based on following the activity of DNA polymerase on individual DNA molecules in real time that occurs on the company’s SMRT Cells, which are monitored and analyzed within its HiFi long-read sequencing systems: the Revio system, Vega system, Sequel system, Sequel II system, and Sequel IIe system. Carried out on SMRTbell templates, which attach hairpin adapters to the ends of double-stranded DNA molecules to be sequenced, SMRT sequencing allows for the successive sequencing of both the forward and reverse strands of the individual DNA molecule occurring multiple times, thereby allowing for the same base of the same molecule to be sequenced more than once in a sequencing run. The base calls from the serial observation of the molecule can be processed to generate the final base call in an analytical procedure called circular consensus sequencing, leading to what the company has defined as its HiFi sequence reads, which have high accuracy typically being defined as having greater than 99% read accuracy, but often exceeding greater than 99.9% accuracy, according to research the company performed in collaboration with other researchers, subsequently published in Nature Biotechnology in 2019. HiFi reads typically are 15-20 kilobases in size, depending on the input fragments, providing sufficient read length with its accuracy to support a multitude of applications across human health, plant and animal, and microbiology, according to research the company performed in collaboration with other researchers, subsequently published in Scientific Data in 2020. According to an article published by Genome Research in 2024, users are able to increase rare disease solve rates using HiFi over short read sequencing. HiFi was also cited as having the ability to resolve complex rearrangements in rare disease cases, subsequently published in an article on Nature.com in 2024.

HiFi Long-Read Sequencing Instruments: Revio system, Vega system, and Sequel systems.

The company’s Revio, Vega, Sequel, Sequel II, and Sequel IIe instruments conduct, monitor, and analyze single-molecule biochemical reactions in real time. The instruments use extremely sensitive imaging systems to collect the light pulses emitted by fluorescent reagents, allowing the observation of biological processes. Computer algorithms are used to translate the information that is captured by the optics system. Using the recorded information, light pulses are converted into either an A, C, G, or T base call with associated quality metrics. Once sequencing is started, the real-time data is delivered to the system’s primary analysis pipeline, which outputs base identity and quality values.

HiFi Consumables

Customers purchase proprietary consumable products to run their PacBio systems, including the company’s SMRT Cells and reagent kits. One SMRT Cell is consumed per sequencing reaction, and scientists can choose the number of SMRT Cells they use per experiment.

The company offers several reagent kits, each designed to address a specific step in the core sequencing workflow. A library preparation kit is used to convert DNA into SMRTbell double-stranded DNA library formats and includes typical molecular biology reagents, such as ligase, buffers, and exonucleases. The company’s binding/polymerase kits include its modified DNA polymerase and are used to bind SMRTbell libraries to the polymerase in preparation for sequencing. The company’s core sequencing kits contain reagents required for on-instrument, real-time sequencing, including phospholinked nucleotides.

The company has developed and is offering a new line of Kinnex kits with companion SMRT Link software to enable high-throughput, scalable, cost-effective RNA applications, including bulk RNA, single-cell RNA, and 16S rRNA sequencing. The Kinnex kits are built upon the Multiplexed Array Sequencing (MAS-Seq) method for concatenating smaller amplicons into larger fragments to sequence on PacBio's long read sequencers, significantly increasing the molecular yield. Throughput increase in these key RNA applications where the dynamic range of different RNA isoforms (bulk and single-cell) or microbial species (16S) can vary by orders of magnitude enables characterization of these complex RNA samples while drastically reducing sequencing need.

SBB Short-Read Sequencing

In contrast to SMRT sequencing, SBB reads short fragments of DNA (hundreds of bases instead of kilobases) in a massively parallel manner. Current short-read next generation sequencing technologies available in the market incur various rates of errors in results. Researchers deploy multiple tactics to try to mitigate these effects, including oversampling or implementing complex library preparation methods, yet still face challenges, including missing rare variants.

Employing a two-phase sequencing chemistry, the SBB approach binds a dye-labeled nucleotide without incorporation into the DNA chain, then removes that base, then blocks and extends with a terminated nucleotide. Using nucleotides with single modifications, the company incorporates more native bases, avoiding potential scarring due to fluorescent linker presence. SBB enables simplified upfront library preparation, redefines coverage requirements, and reduces bioinformatic workload for downstream analysis. The accuracy of its novel sequencing approach has the potential to advance translational cancer research, drive higher fidelity single-cell applications, and broadly enable clinical sequencing—even in regions of the genome prone to sequencing errors with other short-read sequencing technologies.

SBB Short-Read Sequencing Instrument: Onso system.

The company’s Onso instrument conducts, monitors, and analyzes SBB biochemical reactions. The instrument uses extremely sensitive imaging systems to collect the light emitted by fluorescent reagents, allowing the observation of biological processes. Computer algorithms are used to translate the information that is captured by the optics system. Using the recorded information, light pulses are converted into either an A, C, G, or T base call with associated quality metrics. Once sequencing is started, the imaging data is delivered to the system’s primary analysis pipeline, which outputs base identity and quality values.

SBB Consumables

To complement the company’s Onso instrument, it also sells a range of SBB consumable products, including flow cells, clustering, and sequencing reagent kits. One flow cell and associated sequencing reagent pack is consumed per sequencing reaction. Each flow cell contains two lanes, and scientists can choose to sequence different samples in each lane while additionally combining any number of flow cells needed per experiment.

The company offers several reagent kits, each designed to address a specific step in the core sequencing workflow. A library preparation kit is used to convert DNA into SBB compatible, double-stranded DNA library formats and includes typical molecular biology reagents, such as ligase, buffers, and exonucleases. Additionally, for library preparation, the company’s conversion kits include reagents to enable scientists to convert existing sequencing libraries into an SBB compatible format. Finally, the company’s clustering and sequencing kits contain all reagents required for generating sequence ready clusters on flow cell and performing SBB sequencing reactions on instrument, respectively.

Strategy for Growth

The company’s strategies are enabling the full-scale release of the Vega benchtop platform to broaden the company’s market reach; accelerating samples onto the Revio platform via SPRQ chemistry and application kits; investing in future product launches to diversify its offerings; and progressing its clinical strategy to improve outcomes and create durability.

Marketing, Sales, Service, and Support

The company markets its products through a global sales force and through distribution partners in Australia, certain parts of Asia, Europe, the Middle East, Africa, Central America, and South America. The company plans to continue to invest in growing its marketing, sales, service, and support resources as it drives continued adoption of products, launches new products, and expands its customer base.

Customers

The company’s customers include academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations (CROs), pharmaceutical companies, and agricultural companies. In general, its customers will isolate, prepare, and analyze genetic samples using PacBio systems in their own laboratories, or they will send their genetic samples to third-party service providers who, in turn, will sequence the samples with PacBio systems and provide the sequence data back to the customer for further analysis.

Intellectual Property

The company’s current patent portfolio, including patents exclusively licensed to it, is directed to various technologies, including SMRT nucleic acid sequencing and other methods for analyzing biological samples, zero-mode waveguide (ZMW) arrays, surface treatments, phospholinked nucleotides and other reagents for use in nucleic acid sequencing, optical short-read nucleic acid sequencing, nucleic acid preparation, and purification components and systems, processes for identifying nucleotides within nucleic acid sequences, and processes for analysis and comparison of nucleic acid sequence data.

As of December 31, 2024, the company owned or held exclusive licenses to 448 issued U.S. patents, 69 pending U.S. patent applications, 8 pending Patent Cooperation Treaty (PCT) patent applications, 265 issued foreign patents, and 120 pending foreign patent applications. The full term of the issued U.S. patents will expire between 2025 and 2042.

Government Regulation

The company must comply with complex foreign and U.S. laws and regulations, such as the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act, and other local laws prohibiting corrupt payments to governmental officials, anti-competition regulations, and sanctions imposed by the U.S. Office of Foreign Assets Control, and other similar laws and regulations.

Research and Development

The company’s research and development expense decreased to $134.9 million for the year ended December 31, 2024.

History

The company was founded in 2000. The company was incorporated in the state of Delaware in 2000. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005.

Pacific Biosciences of California Questions and Answers

Which sectors generate sales and which are the top 3 markets?

**Industry Revenues:** - **Biotechnology and Genomics** **TOP 3 Markets:** 1. **USA:** approximately 45% 2. **Europe:** approximately 30% 3. **Asia-Pacific:** approximately 20% Pacific Biosciences of California, Inc. generates the majority of its revenues from the biotechnology and genomics indust...

At which locations are the company’s products manufactured?

**Production Site:** Menlo Park, California, USA Pacific Biosciences of California, Inc. primarily produces its products in Menlo Park, California. The company is known for its advanced sequencing technologies and strategically locates its production facilities near its headquarters to efficiently...

What strategy does Pacific Biosciences of California pursue for future growth?

**Focus on Research and Development:** Increase in R&D spending by 20% (2025) **Expansion of Product Range:** Introduction of new sequencing technologies (2025) **Partnerships and Collaborations:** Collaboration with leading research institutions (2024) Pacific Biosciences of California, Inc....

Which raw materials are imported and from which countries?

**Main raw materials:** High-purity silicon wafers, biochemicals, plastics **Countries of origin:** - **High-purity silicon wafers:** USA, Japan - **Biochemicals:** Germany, Switzerland - **Plastics:** China, South Korea Pacific Biosciences of California, Inc. operates in the field of DNA sequenci...

How strong is the company’s competitive advantage?

**Market Share:** Estimated 10% in the field of genome sequencing (2025) **Research and Development Expenditure:** 35% of revenue (2025) **Technological Innovation:** High precision in long-read sequencing Pacific Biosciences of California, Inc. has gained a significant competitive advantage...

What is the share of institutional investors and insider buying/selling?

**Institutional Investor Share:** 70% (estimated, based on historical data and trends from 2023) **Insider Buys/Sells:** No specific data available for 2026, but based on recent years, there have been regular insider sells, which could indicate profit-taking. The institutional investor share at Pa...

What percentage market share does Pacific Biosciences of California have?

**Market share of Pacific Biosciences:** Estimated 12% (2026) **Major competitors and their market shares:** 1. **Illumina, Inc.:** 35% 2. **Thermo Fisher Scientific Inc.:** 20% 3. **Oxford Nanopore Technologies plc:** 15% 4. **Pacific Biosciences of California, Inc.:** 12% 5. **BGI Group:** 10% 6....

Is Pacific Biosciences of California stock currently a good investment?

**Revenue Growth:** 18% (2025) **Research & Development (R&D) Expenses:** 35% of revenue (2025) **Market Share in Genomic Sequencing:** 10% (2025) Pacific Biosciences of California, Inc. recorded an impressive revenue growth of 18% in 2025. This indicates strong demand for their genomic seq...

Does Pacific Biosciences of California pay a dividend – and how reliable is the payout?

**Dividend:** No payout (as of 2026) Pacific Biosciences of California, Inc. currently does not pay a dividend. The company has focused in the past on investing its resources in research and development as well as expanding its business activities. As Pacific Biosciences operates in a technologica...

New support ticket

Explore

Pacific Biosciences of California Stock Value

Pacific Biosciences of California Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Pacific Biosciences of California do?

Pacific Biosciences of California Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

Pacific Biosciences of California Stock Value

Pacific Biosciences of California Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Pacific Biosciences of California do?

Pacific Biosciences of California Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.